— Know what they know.
Not Investment Advice

NBY AMEX

NovaBay Pharmaceuticals, Inc.
1W: +25.3% 1M: +27.0% 3M: -93.6% YTD: -93.6% 1Y: -0.5% 3Y: -99.0% 5Y: -100.0%
$1.47
Last traded 2026-04-06 — delisted
AMEX · Healthcare · Biotechnology · $39.1M mcap · 26M float · 2.09% daily turnover · Short 33% of daily vol

Balance Sheet Trends

Total Assets
$9M +163.9% ▲
5Y CAGR: -9.9%
Total Liabilities
$32M +797.0% ▲
5Y CAGR: +61.3%
Shareholders Equity
-$23M -17594.6% ▼
Cash & Investments
$8M +1750.7% ▲
5Y CAGR: -7.8%
Total Debt
$776K -53.6% ▼
5Y CAGR: +9.1%
Net Debt
-$7M -678.3% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$8M$5M$3M$430K$8M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$8M$5M$3M$430K$8M
Net Receivables$2M$2M$759K$389K$0
Inventory$3M$3M$3M$765K$0
Other Current Assets$129K$159K$81K$158K$717K
Total Current Assets$13M$11M$7M$2M$9M
Property, Plant & Equip.$604K$2M$1M$1M$0
Goodwill & Intangibles$10M$3M$0$0$0
Long-Term Investments$0$0$0$477K$267K
Other Non-Current Assets$476K$489K$497K$3K$93K
Total Non-Current Assets$11M$5M$2M$1M$360K
Total Assets$24M$16M$9M$3M$9M
— Liabilities —
Accounts Payable$1M$1M$1M$623K$257K
Short-Term Debt$105K$0$1M$565K$489K
Deferred Revenue$1M$2M$0$488K$0
Other Current Liabilities$0$0$1M$172K$396K
Total Current Liabilities$3M$4M$4M$3M$1M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$10M$0$334K$0$30M
Total Non-Current Liabilities$10M$2M$1M$709K$31M
Total Liabilities$14M$6M$6M$4M$32M
— Equity —
Common Stock$478K$20K$112K$49K$252K
Retained Earnings-$142M-$158M-$175M-$183M-$210M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$10M$11M$3M-$129K-$23M
Total Liabilities & Equity$24M$16M$9M$3M$9M
— Key Metrics —
Total Debt$551K$2M$3M$2M$776K
Net Debt-$7M-$3M-$390K$1M-$7M
Total Investments$0$0$0$477K$267K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms